My SciELO
Services on Demand
article
Indicators
Cited by SciELO
Related links
Bookmark
Revista Cubana de Pediatría
On-line version ISSN 1561-3119
Abstract
DE LA GUARDIA PENA, Odalis María; ESPINASO KUAN, Joan; PLANAS VIATEL, Tarsis and SABIGNE LAMOTE, Magdalena. Jalea Real (tabletas masticables) una alternativa en el tratamiento de pacientes pediátricos con inmunodeficiencia celular. Rev Cubana Pediatr [online]. 2004, vol.76, n.1, pp. 0-0. ISSN 1561-3119.
In order to evaluate the efficacy of the use of Royal Jelly (chewable tablets) in children with cellular immunodeficiencies, 100 children that were diagnosed this affection at the Immunology Department of "Juan Cruz Martínez Maceira" Northern Children Teaching Hospital, in Santiago de Cuba, from 200 to 2002, were studied. 3 groups of treatment were established: group 1, usual treatment with levamisol and vitamins; group 2, usual treatment plus half of the optimun dose of Royal Jelly; group 3, Royal Jelly at optimum dose. A higher clinical and laboratory improvement was observed among patients using Royal Jelly. No adverse reactions were detected and there was an increase of the quality of life and of appetite . A rise of the peripheral T lymphocytes count was also proved by Roseta test. When the Royal Jelly was mixed with levamisol, the appearance of neutropenia decreased considerably. According to the results of this study, the Royal Jelly may be used as a cellular immunomodulator.
Keywords : BEES; INMUNOLOGIC DEFICIENCY SYNDROMES [drug therapy]; TABLETS [therapeutic use]; PLANT EXTRACTS [therapeutic use]; CHILD.











